Our Pricing

Ozempic & Mounjaro In Stock - Order Today UK

Published on: June 03, 2026

When you buy Mounjaro online UK pharmacy services, availability and transparency matter. At Cured Pharmacy, we maintain consistent stock of Mounjaro (tirzepatide) and Wegovy (semaglutide) weight loss injections, with upfront pricing from £124.99 and same-day dispatch available. Our UK-registered prescribers complete your free clinical assessment in under 3 minutes, and all medications are dispensed by our GPhC-registered team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

How Mounjaro Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

In the SURMOUNT-1 clinical trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% in the placebo group [1]. The dual-receptor mechanism appears to produce superior weight loss outcomes compared to GLP-1-only treatments, though individual results vary based on adherence, baseline BMI, and lifestyle factors.

Tirzepatide works by slowing gastric emptying, reducing appetite signals in the hypothalamus, and improving post-meal glucose control. Most patients report feeling fuller sooner during meals and experiencing fewer food cravings between eating occasions, though these effects typically develop gradually over the first 4-8 weeks of treatment [2].

Mounjaro vs Wegovy: Comparing GLP-1 Weight Loss Treatments

Both Mounjaro and Wegovy are once-weekly injectable medications licensed in the UK for chronic weight management, but they operate through different receptor pathways. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro's tirzepatide targets both GIP and GLP-1 receptors simultaneously.

Clinical trial data suggests tirzepatide may produce greater average weight loss than semaglutide. In head-to-head comparisons, the SURPASS-2 trial demonstrated that tirzepatide 15mg resulted in superior weight reduction compared to semaglutide 1mg over 40 weeks [3]. However, both medications have proven efficacy, and the choice between them depends on individual medical history, side effect tolerance, and prescriber assessment.

Side effect profiles are similar for both treatments, with nausea, diarrhoea, and constipation being the most commonly reported adverse events. These gastrointestinal symptoms typically diminish after the initial titration period. Your UK prescriber will consider your previous medication responses, existing health conditions, and treatment goals when recommending the most appropriate option.

Which Treatment Is Right for You?

The decision between Mounjaro and Wegovy should be made in consultation with a UK-registered prescriber who can assess your complete medical profile. Factors influencing treatment selection include your BMI, presence of type 2 diabetes, previous weight loss attempts, cardiovascular risk factors, and budget considerations. At Cured Pharmacy, our clinical team evaluates these factors during your free online consultation to recommend the most suitable medication, subject to clinical appropriateness and supply availability.

Stock Availability and UK Delivery Options

Supply chain challenges have affected weight loss injection availability across UK pharmacies throughout 2024 and early 2025. At Cured Pharmacy, we maintain direct relationships with licensed UK wholesalers to secure consistent stock of Mounjaro pens across all maintenance doses. Our online stock indicator is updated in real-time, and we never accept payment for out-of-stock medications.

Once your prescription is approved by our UK prescriber, orders placed before 3pm Monday-Friday are typically dispatched the same working day via Royal Mail Tracked 24 or DHL courier service. All packaging is completely discreet with no external markings indicating pharmacy or medication contents. Delivery to most UK mainland addresses occurs within 1-2 working days, with Saturday delivery available for an additional fee.

For patients requiring ongoing treatment, we offer a convenient repeat prescription service. After your initial clinical assessment, our prescribers can issue repeat prescriptions for up to 6 months, allowing you to reorder without completing a full consultation each time. You'll receive email reminders before your current supply runs out, ensuring continuity of treatment without interruption.

Managing Supply Interruptions

If your prescribed medication becomes temporarily unavailable, our clinical team will contact you to discuss suitable alternatives with equivalent efficacy. We never substitute prescription medications without explicit prescriber approval and patient consent. In cases of extended supply disruption, we may recommend switching to an alternative GLP-1 treatment or adjusting your treatment plan in consultation with your prescriber.

Transparent Pricing: What You'll Actually Pay

At Cured Pharmacy, Mounjaro pens start from £124.99, with your final cost determined by the specific dose prescribed after clinical assessment. Unlike some online services, we display all pricing before you begin your consultation, with no hidden fees added at checkout. Our pricing includes the medication, UK prescriber consultation, dispensing by our GPhC-registered pharmacy team, and standard tracked delivery.

We operate a lowest price guarantee across our weight loss treatment range. If you find a lower price for the same medication and dose at another UK-registered pharmacy, we'll match it. This commitment extends to all our GLP-1 treatments, ensuring you receive both clinical excellence and competitive value.

Payment is processed securely after your prescription is approved but before dispatch. We accept all major credit and debit cards, and your card statement will show a discreet descriptor without reference to the medication type. Patients using private medical insurance should check their policy coverage, as some insurers now cover weight management medications when prescribed for clinical obesity.

The Online Consultation Process at Cured Pharmacy

Our free online medical consultation typically takes under 3 minutes to complete and covers essential clinical safety questions. You'll provide information about your current weight and height, existing medical conditions, current medications, previous weight loss attempts, and any history of thyroid disease or pancreatitis. This information allows our UK-registered prescribers to determine whether GLP-1 treatment is clinically appropriate for you.

All consultations are reviewed by GMC-registered doctors or GPhC-registered prescribers with specialist training in obesity management. They assess your responses against NICE guidelines and MHRA licensing criteria, which generally require a BMI of 30 or above, or 27 or above with weight-related health conditions. If your consultation raises any clinical concerns, our prescriber may request additional information or recommend an alternative treatment approach.

Most consultation reviews are completed within 24 hours on working days, though many are approved much faster. You'll receive email notification as soon as your prescription is approved, and you can track your order status through your Cured Pharmacy account. If your consultation cannot be approved, you'll receive a full refund and explanation of the clinical reasons, along with alternative recommendations where appropriate.

What Happens If I'm Not Suitable?

Not all patients are suitable candidates for GLP-1 weight loss treatments. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or pregnancy and breastfeeding. If our prescriber determines that Mounjaro or similar treatments aren't appropriate for you, we'll suggest alternative weight management options such as Orlistat or Mysimba, which work through different mechanisms and may be more suitable for your clinical profile.

Starting Treatment: Dosing and What to Expect

Mounjaro treatment follows a gradual dose escalation schedule to minimise gastrointestinal side effects. Most patients begin with the 2.5mg starter dose, administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm. After 4 weeks, the dose typically increases to 5mg, then continues escalating every 4 weeks until reaching the maintenance dose that provides optimal weight loss with tolerable side effects [4].

The maximum licensed dose is 15mg once weekly, though many patients achieve their weight loss goals at lower maintenance doses. Your prescriber will guide you through the titration schedule and may adjust the escalation pace if you experience persistent nausea or other side effects. It's important not to increase your dose faster than prescribed, as this significantly increases the risk of adverse gastrointestinal reactions.

Most patients begin noticing appetite reduction within 1-2 weeks of starting treatment, with measurable weight loss typically becoming apparent after 4-8 weeks. Clinical trials showed that the majority of weight loss occurs within the first 36 weeks of treatment, after which weight tends to stabilise at a new baseline [1]. Combining medication with dietary modifications and increased physical activity enhances outcomes, and our clinical team can provide guidance on evidence-based lifestyle strategies to maximise your results.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. Retrieved from https://products.mhra.gov.uk/ [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, diet, and physical activity levels.